ONCONOVA THERAPEUTICS, INC.

Basic Information

375 PHEASANT RUN
NEWTOWN, PA, 18940-3423

Company Profile

n/a

Additional Details

Field Value
DUNS: 66821492
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of a Selective PLK2 Inhibitor for Cancer Therapy

    Amount: $275,861.00

    DESCRIPTION (provided by applicant): The recent success of imatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia has made tyrosine and serine/threonine kinases ...

    SBIR Phase I 2011 Department of Health and Human Services
  2. Development of a Small Molecule-Targeted Therapy for Mantle Cell Lymphoma

    Amount: $220,180.00

    DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL) that accounts for 5- 8% of all lymphoma cases. The disease is typically found i ...

    SBIR Phase I 2008 Department of Health and Human Services
  3. Identification of Small Pharmacologic Inhibitors of HIV-1 Replication

    Amount: $203,744.00

    DESCRIPTION (provided by applicant): HIV is the causative agent of AIDS (Acquired Immunodeficiency Syndrome). In 2005 the estimated number of individuals living with AIDS worldwide was about 40.3 mill ...

    STTR Phase I 2007 Department of Health and Human Services
  4. Evaluation of novel cytotoxic compounds for immunoconjugates

    Amount: $155,103.00

    DESCRIPTION (provided by applicant): The remarkable commercial and medical success of monoclonal antibodies has led to the exploration of variations of this therapeutic modality. One approach, which i ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. Use of Novel Cox-2 Inhibitors in Neurological Disorders

    Amount: $845,883.00

    DESCRIPTION (provided by applicant): Strategies aimed at limiting and repairing the damage attributed to oxidative stress may slow the advance of numerous age-related diseases. Numerous studies indica ...

    SBIR Phase II 2005 Department of Health and Human Services
  6. Novel Cyclooxygenase-2 Inhibitors: Epileptogenesis

    Amount: $218,796.00

    DESCRIPTION (provided by applicant): Nearly 3% of the population in the United States has been diagnosed with some form of epilepsy at an estimated annual cost of >$12 billion. A major goal of transl ...

    SBIR Phase I 2005 Department of Health and Human Services
  7. Novel Therapeutic Strategy for Gliomas

    Amount: $135,546.00

    DESCRIPTION (PROVIDED BY APPLICANT): Malignant gliomas are characterized by their ability to swiftly and diffusely invade from their primary foci into the surrounding normal brain parenchyma, making t ...

    SBIR Phase I 2005 Department of Health and Human Services
  8. Pre-clinical Developmemt of a Novel COX-2 Inhibitor

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Up-regulation of COX-2 has been reported to occur in cancer cells and selective inhibition of COX-2 has been demonstrated to reduce cancer cell growth in animal mo ...

    SBIR Phase I 2003 Department of Health and Human Services
  9. Use of Novel Cox-2 Inhibitors in Neurological Disorders

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Up-regulation of COX-2 has also been reported to occur in human brains following a lethal cerebral ischemic insult and selective inhibition of COX-2 has been demon ...

    SBIR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government